bioasis technologies, inc. presentation - october 2014
Post on 21-Jun-2015
33 Views
Preview:
DESCRIPTION
TRANSCRIPT
A na
tura
l sol
utio
n to!
deliv
er m
edic
ines
to!
the
brai
n!
OCT
OBE
R!
2014
!bi
Oas
is.ca
!
OTC
QX:
BIO
AF!
TSX.
V: B
TI!
OTCQ
X: B
IOAF
TS
X.V:
BTI
Forw
ard
Look
ing S
tate
men
ts
Certa
in s
tate
men
ts in
this
pres
s re
leas
e co
ntai
n fo
rwar
d-lo
okin
g st
atem
ents
with
in th
e m
eani
ng o
f the
Priv
ate
Secu
ritie
s Li
tigat
ion
Refo
rm A
ct o
f 19
95 o
r fo
rwar
d-lo
okin
g in
form
atio
n un
der
appl
icab
le C
anad
ian
secu
ritie
s le
gisla
tion
that
may
not
be
base
d on
hi
stor
ical
fact
, inc
ludi
ng w
ithou
t lim
itatio
n st
atem
ents
con
tain
ing
the
wor
ds “
belie
ve”,
“may
”, “p
lan”
, “w
ill”, “
estim
ate”
, “co
ntin
ue”,
“ant
icip
ate”
, “in
tend
”, “e
xpec
t” a
nd s
imila
r exp
ress
ions
. Suc
h fo
rwar
d-lo
okin
g st
atem
ents
or i
nfor
mat
ion
invo
lve k
now
n an
d un
know
n ris
ks, u
ncer
tain
ties
and
othe
r fac
tors
that
may
cau
se o
ur a
ctua
l res
ults
, eve
nts
or d
evel
opm
ents
, or i
ndus
try re
sults
, to
be m
ater
ially
diffe
rent
from
any
futu
re re
sults
, eve
nts
or d
evel
opm
ents
exp
ress
or i
mpl
ied
by s
uch
forw
ard-
look
ing
stat
emen
ts o
r inf
orm
atio
n.
Such
fact
ors
incl
ude,
am
ong
othe
rs, o
ur s
tage
of d
evel
opm
ent,
lack
of a
ny p
rodu
ct re
venu
es, a
dditi
onal
cap
ital r
equi
rem
ents
, risk
as
soci
ated
with
the
com
plet
ion
of c
linic
al tr
ials
and
obta
inin
g re
gula
tory
app
rova
l to
mar
ket o
ur p
rodu
cts,
the
abilit
y to
pro
tect
our
in
telle
ctua
l pro
perty
, dep
ende
nce
on c
olla
bora
tive
partn
ers
and
the
pros
pect
s fo
r neg
otia
ting
addi
tiona
l cor
pora
te c
olla
bora
tions
or
licen
sing
arra
ngem
ents
and
thei
r tim
ing.
Spe
cific
ally,
cer
tain
risk
s an
d un
certa
intie
s th
at c
ould
cau
se s
uch
actu
al e
vent
s or
resu
lts
expr
esse
d or
impl
ied
by s
uch
forw
ard-
look
ing
stat
emen
ts a
nd in
form
atio
n to
diff
er m
ater
ially
fro
m a
ny f
utur
e ev
ents
or
resu
lts
expr
esse
d or
impl
ied
by s
uch
stat
emen
ts a
nd in
form
atio
n in
clud
e, b
ut a
re n
ot li
mite
d to
, the
risk
s an
d un
certa
intie
s th
at: p
rodu
cts
that
we
deve
lop
may
not
suc
ceed
in p
recl
inic
al o
r clin
ical
tria
ls, o
r fut
ure
prod
ucts
in o
ur ta
rget
ed c
orpo
rate
obj
ectiv
es; o
ur fu
ture
op
erat
ing
resu
lts a
re u
ncer
tain
and
like
ly to
fluc
tuat
e; w
e m
ay n
ot b
e ab
le to
raise
add
ition
al c
apita
l; w
e m
ay n
ot b
e su
cces
sful
in
esta
blish
ing
addi
tiona
l cor
pora
te c
olla
bora
tions
or l
icen
sing
arra
ngem
ents
; we
may
not
be
able
to e
stab
lish
mar
ketin
g an
d th
e co
sts
of la
unch
ing
our
prod
ucts
may
be
grea
ter
than
ant
icip
ated
; w
e ha
ve n
o ex
perie
nce
in c
omm
erci
al m
anuf
actu
ring;
we
may
fac
e un
know
n ris
ks r
elat
ed t
o in
telle
ctua
l pr
oper
ty m
atte
rs;
we
face
inc
reas
ed c
ompe
titio
n fro
m p
harm
aceu
tical
and
bio
tech
nolo
gy
com
pani
es;
and
othe
r fa
ctor
s as
des
crib
ed i
n de
tail
in o
ur fi
lings
with
the
Can
adia
n se
curit
ies
regu
lato
ry a
utho
ritie
s at
w
ww.
seda
r.com
.
2"
Give
n th
ese
risks
and
unc
erta
intie
s, y
ou a
re c
autio
ned
not t
o pl
ace
undu
e re
lianc
e on
suc
h fo
rwar
d-lo
okin
g st
atem
ents
and
info
rmat
ion,
whi
ch a
re q
ualifi
ed in
the
ir en
tiret
y by
thi
s ca
utio
nary
sta
tem
ent.
All f
orw
ard-
look
ing
stat
emen
ts a
nd in
form
atio
n m
ade
here
in a
re b
ased
on
our c
urre
nt e
xpec
tatio
ns a
nd w
e un
derta
ke n
o ob
ligat
ion
to re
vise
or u
pdat
e su
ch fo
rwar
d- lo
okin
g st
atem
ents
and
info
rmat
ion
to re
flect
sub
sequ
ent e
vent
s or
circ
umst
ance
s, e
xcep
t as
requ
ired
by la
w.
OTCQ
X: B
IOAF
TS
X.V:
BTI
Cent
ral N
ervo
us S
yste
m D
iseas
es
3"
1) (
2012
). Br
ain
Fact
s; A
Prim
er o
n th
e Br
ain
and
Nerv
ous
Syst
em .
Publ
icat
ion,
Soc
iety
for N
euro
scie
nce.
2) (
2007
). Ne
urol
ogic
al d
isord
ers:
Pub
lic h
ealth
cha
lleng
es .
Stud
y, UN
Wor
ld H
ealth
Org
aniza
tion
. 3) b
cc R
esea
rch
. (20
10, S
epte
mbe
r ). T
hera
peut
ic D
rugs
for C
entra
l Ner
vous
Sys
tem
(CNS
) Diso
rder
s: T
echn
olog
ies
and
Glo
bal M
arke
ts,
PHM
068A
.
AFFE
CTS
1 IN
6 P
EOPL
E !
ALL
TREA
TMEN
TS H
INDE
RED
BY T
HE B
LOO
D BR
AIN
BARR
IER
!
12%
of G
lobal
Deat
hs1
12%
Incr
ease
by
2030
1 >1
000
Diffe
rent
Di
seas
es2
>$50
0 Bi
llion
US
Mar
ket2
>$81
.2 B
illion
Drug
M
arke
t3
OTCQ
X: B
IOAF
TS
X.V:
BTI
" Chall
enge
" Th
e Bl
ood
Brain
Bar
rier (
“BBB
”)
Prot
ectiv
e ba
rrier
of t
he c
entra
l ner
vous
sys
tem
(“C
NS”)
prev
entin
g to
xic c
ompo
unds
from
ent
ering
th
e br
ain fr
om th
e cir
culat
ory
syst
em
Prob
lem
BBB
prev
ents
ther
apeu
tics
from
ent
ering
the
brain
in
effic
acio
us le
vels
• ~9
8% o
f sm
all m
olec
ule d
rugs
•
~100
% o
f larg
e m
olec
ule d
rugs
1
Solut
ion
• bi
Oas
is ha
s di
scov
ered
a n
atur
al oc
curri
ng
phys
iolo
gica
l pro
cess
that
can
tran
spor
t th
erap
eutic
s ac
ross
the
BBB
4"
1) R
oyal
Soc
iety
of C
hem
istry
Tight
ly wo
ven
capil
lary n
etwo
rk o
f en
doth
elial
cells
lining
the
blood
vess
els in
th
e br
ain, w
hich
is re
spon
sible
for
main
taini
ng h
omeo
stas
is
OTCQ
X: B
IOAF
TS
X.V:
BTI
Wha
t we
do…
Drug
Deli
very
Plat
form
Pa
tent
ed fa
mily
of c
arrie
rs, w
hich
deliv
ers
med
icine
s ac
ross
the
BBB
for t
he tr
eatm
ent o
f CN
S di
seas
es
Pote
ntial
trea
tmen
ts fo
r:
Mar
ket L
eadi
ng Te
chno
logy
Th
e Tr
ansc
end
Prog
ram
5"
Brain
Can
cers
M
etab
olic
Dise
ases
Ne
urod
egen
erat
ive
Dise
ases
OTCQ
X: B
IOAF
TS
X.V:
BTI
Brea
kthr
ough
Sol
utio
n
MTf
• Kn
own
as M
elano
trans
ferri
n (M
Tf o
r p97
) •
Hum
an p
rote
in fo
und
at lo
w c
once
ntra
tions
in th
e bl
ood
• Na
tura
lly d
elive
rs ir
on to
the
brain
•
Tech
nolo
gy p
aten
ted
by th
e Un
ivers
ity o
f Brit
ish
Colum
bia;
late
r acq
uired
by
biO
asis
6"
The
Tran
scen
d Pr
ogra
m
A na
tura
lly o
ccur
ring
biol
ogica
l pro
cess
that
can
be
expl
oite
d to
deli
ver t
hera
peut
ics a
cros
s th
e BB
B an
d int
o th
e br
ain ti
ssue
to tr
eat m
any
neur
olog
ical d
iseas
es a
nd b
rain
diso
rder
s
MTf
p
• A
new
ly di
scov
ered
pep
tide
foun
d w
ithin
the
full
lengt
h pr
otein
(MTf
), w
hich
offe
rs im
prov
ed b
rain
pene
tratio
n an
d gr
eate
r com
mer
cial p
oten
tial
OTCQ
X: B
IOAF
TS
X.V:
BTI
Adva
ntag
e of
MTf
p
!
Gre
ater
effic
iency
of B
BB d
elive
ry
!
Low
er c
ost o
f pro
duct
ion
!
Impr
oved
qua
lity c
ontro
l !
Sim
pler
to lin
k to
ther
apeu
tics
!
Tran
spor
ts a
var
iety
of c
ompo
unds
w
ith n
o ap
pare
nt s
ize lim
itatio
n !
Exte
nds
biO
asis
pate
nt p
ortfo
lio
!
Phar
mac
eutic
al co
llabo
rato
rs
curre
ntly
licen
sing
MTf
p
7"
BBB"
MTf
p in
Actio
n
MTf
p Th
erap
eutic
OTCQ
X: B
IOAF
TS
X.V:
BTI
Mar
ket O
ppor
tunit
ies
Majo
r Unm
et M
edica
l Nee
d 20
14 D
rug
Mar
ket E
stim
ates
8"
A ca
rrier t
o cr
oss
the
BBB
would
est
ablis
h a
foot
hold
with
in th
ese
majo
r mar
kets
Ce
ntra
l Ner
vous
Sy
stem
Di
sord
ers
!
Stro
ke &
Tr
aum
atic
Brain
Injur
y In
fect
ion
Lyso
som
al !
Stor
age
Dise
ase !
~$20
Billio
n �
USD
~$81
.2 Bi
llion �
USD
~$7.5 Bi
llion �
USD
>$1.9 Bi
llion �
USD
~$33
.7 Bi
llion �
USD
~$13
8 Billio
n �
USD
~$32
.3
Psyc
hiatry
Billio
n �
USD
Ne
urod
egen
erat
ive
Dise
ase"
Clini
cal
need
met
but
im
prov
ed
BBB
pene
tratio
n
could
inc
reas
e
effica
cy
Pain
& M
igra
ine
"
OTCQ
X: B
IOAF
TS
X.V:
BTI
Brain
Can
cer M
arke
t 20
13 D
rug
Sales
for C
ance
rs, w
hich
frequ
ently
m
etas
tasiz
e in
the
brain
2
9"
1) G
loba
lDat
a “B
rain
Tum
or –
Pip
elin
e As
sess
men
t and
Mar
ket F
orec
asts
to 2
017”
rele
ased
Jan
. 17,
201
1.
2) C
ompa
ny R
epor
ted
Data
Herc
eptin
® (t
rast
uzum
ab)
HER2
+ Br
east
Can
cer
~40%
Met
asta
size
Taxo
l® (P
aclit
axel)
Lung
, ova
rian,
etc.
~35%
Met
asta
size
Ritu
xan®
(Ritu
ximab
) Bl
ood
canc
ers:
lymph
oma,
leuke
mia,
etc.
~24%
Met
asta
size
Erbi
tux®
(Cet
uxim
ab)
Lung
canc
er, co
lon ca
ncer,
etc.
~35%
Met
asta
size
$6.6 Bi
llion �
USD
$7.5 Bi
llion �
USD
$1.9 Bi
llion �
USD
$92 M
illion �
USD
Main!
G
loba
l Bra
in Tu
mou
r Th
erap
ies1
~$
1.4 Bi
llion �
USD
OTCQ
X: B
IOAF
TS
X.V:
BTI
Busin
ess
Opp
ortu
nity
10"
Pate
nt C
liff
Estim
ated
~$2
50 b
illion
in lo
st
reve
nue
from
pat
ent
expi
ratio
ns fr
om 2
012-
2015
1
" 1)
DeRuiter,"J.,"&"Holston,"P."L."(2012,"June"20)."Drug"Patent"ExpiraEons"and"the"“Patent"Cliff”."U.S."Pharm
."2012;37(6)(Generic"suppl):12S20."
2)
"(2007)."Neurological"disorders:"Public"health"challenges"."Study,"UN"W
orld"Health"OrganizaEon"."
hZp://w
ww.un.org/apps/news/story.asp?newsid=21689&cr=neurological#.U7iNnBa4klI"
3)
(2012)."Brain"Facts;"A"Primer"on"the"Brain"and"Nervous"System"."PublicaEon,"Society"for"Neuroscience."
Mar
ket G
row
th
CNS
Drug
Mar
ket w
orth
ove
r $8
1.2
billio
n US
D an
d gr
owing
at
12%
CAG
R (2
012-
2030
)3
"
Unm
et M
edica
l Nee
d O
ver 1
000
uniq
ue C
NS d
iseas
es
with
trea
tmen
ts h
inder
ed b
y dr
ug
deliv
ery
acro
ss th
e BB
B2
"
Offe
rs th
e po
tent
ial fo
r pat
ent
term
exte
nsion
s th
roug
h Ne
w Ch
emica
l Ent
ity (“
NCE”
) on
man
y pre
exist
ing d
rugs
Aid
in th
e de
velop
men
t of n
ew
ther
apies
and
revit
alize
dor
man
t ca
ndida
tes
that
are
pro
ven
effica
cious
but
do
not c
ross
Cont
ribut
e CN
S dr
ug m
arke
t by
open
ing u
p an
indu
stry
that
has
be
en s
tagn
ated
by i
neffe
ctive
br
ain d
rug
deliv
ery
OTCQ
X: B
IOAF
TS
X.V:
BTI
Who
we
are…
Boar
d of
Dire
ctor
s
Rob
Hutc
hison
, Cha
ir &
CEO
Form
er: C
EO &
Chie
f Scie
ntist
at e
Char
ge C
orpo
ratio
n
Chris
Fib
iger
, PhD
Fo
rmer
: Hea
d of
Neu
rosc
ience
, Am
gen;
VP
Neur
oscie
nce,
Eli L
ily &
CS
O, B
iova
il Lab
orat
ories
Gre
g G
ubitz
, LLB
Fo
rmer
: VP,
Bio
vail C
orpo
ratio
n &
COO
, MDS
Cap
ital
Terry
Pea
rson
, PhD
Pr
ofes
sor:
Bioc
hem
istry
& M
icrob
iolo
gy, U
VIC
Ron
Erick
son
Curre
nt: C
hair
& CE
O, V
isulan
t Tec
hnol
ogies
M
ichae
l Hut
chiso
n, Q
C, L
LB
Partn
er, S
mith
Hut
chiso
n La
w C
orpo
ratio
n
Team
Judi
Dall
ing, L
LB, C
FO
Seas
oned
pub
lic c
ompa
ny C
FO a
nd c
orpo
rate
law
yer
Wilfr
ed J
effe
ries,
PhD
, Fou
nding
Scie
ntist
O
xfor
d Un
ivers
ity, M
olec
ular I
mm
unol
ogy
Disc
over
ed p
97’s
abilit
y to
cro
ss th
e BB
B Pr
ofes
sor:
Micr
obio
logy
& Im
mun
olog
y, UB
C Re
inhar
d G
abat
huler
, PhD
, Chie
f Scie
ntist
Form
er: V
P Br
ain R
esea
rch,
Bio
mar
in &
CSO
, Ang
ioch
em In
c.
Mei
Mei
Tian
, PhD
, Scie
ntist
UB
C, M
icrob
iolo
gy a
nd Im
mun
olog
y (p
97 e
xper
tise)
La
ura
Ho, M
Sc, S
cient
ist
UBC,
Micr
obio
logy
and
Imm
unol
ogy
Tiffa
ny To
lmie,
Com
mun
icatio
ns
Hono
urs,
Wilfr
id L
aurie
r Univ
ersit
y
OTCQ
X: B
IOAF
TS
X.V:
BTI
Inde
pend
ent
3rd
party
va
lidat
ion
Expa
nd &
pr
otec
t In
telle
ctu
al
Pro
pert
y
Adva
nce
inter
nal
deve
lopm
ent
prog
ram
s
Colla
bora
te
with
repu
tabl
e ph
arm
aceu
tical
com
panie
s
Corp
orat
e St
rate
gy
12"
• Lo
w-c
ost p
rojec
ts
• Po
tent
ial to
ach
ieve
majo
r mile
ston
es:
"
Sho
rt-M
id-L
arge
M
arke
t Pot
entia
l
• M
any
“sho
ts o
n g
oal”
leadi
ng to
com
mer
cial
trans
actio
ns w
ith
num
erou
s pa
rtner
s/lic
ense
es
• O
ver 3
0 pa
tent
s gr
ante
d fo
r BBB
de
liver
y an
d ne
urod
egen
erat
ive
dise
ases
• Na
tiona
l Res
earc
h Co
uncil
•
BC C
ance
r Res
earc
h Ce
ntre
•
Texa
s Te
ch U
niver
sity
Healt
h Sc
ience
s Ce
nter
• So
uthe
rn R
esea
rch
Inst
itute
• Un
ivers
ity o
f Alab
ama
OTCQ
X: B
IOAF
TS
X.V:
BTI
Colla
bora
tions
Stra
tegi
c Co
llabo
ratio
ns
• Ab
bVie
• M
edIm
mun
e •
UCB
Phar
mac
eutic
als
MTf
p
• M
edIm
mun
e ex
ecut
ed L
icens
e Ag
reem
ent
• O
n-go
ing d
iscus
sions
with
col
labor
ator
s fo
r lic
ensin
g ag
reem
ents
•
Furth
er d
iscus
sions
with
larg
e ph
arm
aceu
tical
com
panie
s on
licen
sing
and
rese
arch
op
portu
nities
13"
OTCQ
X: B
IOAF
TS
X.V:
BTI
MTf
: Rap
id U
ptak
e in
Brain
14"
Com
poun
d Br
ain K
in (m
L-1/
s-1 /
g-1 )
Refe
renc
e
Glu
cose
9.
5 x
10-3
Smith
(200
3)
Mel
anot
rans
ferri
n (M
Tf) !
6.4
x 10
-4 !
Dem
eule
et a
l. (2
002)!
Mor
phin
e 2.
0 x
10-4
Cist
erni
no e
t al.
(200
1)
Apro
tinin
!1.
6 x
10-4
De
meu
le e
t al.
(200
8)
Insu
lin R
ec A
ntib
ody !
1.0
x 10
-4
Pard
ridge
(199
7)
Leu-
Enke
phal
in
6.0
x 10
-5
Zlok
ovic
(19
87)
Mor
phin
e-6-
Glu
curo
nide
2.
4 x
10-5
Tem
sam
ani e
t al.
(200
5)
RAP
!1.
0 x
10-5
Pa
n (2
004)
Beta
Am
yloid
6.
5 x
10-6
Ba
nks
(199
1)
DADL
E 6.
5 x
10-6
Ch
en (2
002)
TNF-α
4.3
x 10
-6
Pan
(200
2)
Tran
spor
t Effi
cien
cy
Mor
e
Less
In Si
tu B
rain
Upta
ke –
Mea
sure
men
t of R
ate
of Tr
ansp
ort
Competitors""
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
ams:
"M
Tf +
Ant
i-Aβ
antib
ody
Resu
lts
MTf
+ a
nti-A
β an
tibod
y co
njuga
te in
crea
ses
trans
port
into
brain
tiss
ue b
y ~5-
fold
Qua
ntita
tive
Imag
e An
alys
is b
y La
ser
Scan
ning
Con
foca
l Mic
rosc
opy
15"
Alzh
eimer
’s Di
seas
e
Anti-
Aβ a
ntib
odies
hav
e un
derg
one
clinic
al tri
als fo
r tre
atm
ent o
f Alzh
eimer
’s di
seas
e
Opp
ortu
nity
Using
ant
ibod
ies d
irect
ed a
t Aβ
are
pot
entia
l the
rape
utics
fo
r red
ucing
am
yloid
plaq
ues
in th
e br
ain
Na
tiona
l Res
earc
h Co
unci
l of C
anad
a (N
RC)
Anti-
Aβ
MTf
+ A
nti-A
β
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
am:"
MTf
+ α
-L-id
uron
idas
e (“I
DU”)
Lyso
som
al St
orag
e Di
seas
es
Rare
inhe
rited
met
abol
ic di
seas
es c
ause
d by
an
enzy
me
defic
iency
prim
arily
affe
cting
chil
dren
Hurle
r Syn
drom
e (M
PS I)
Prob
lem
• M
PS I
is ca
used
by
an ID
U de
ficien
cy
• Cu
rrent
ly CN
S ef
fect
s un
treat
able
Resu
lts
• M
Tf +
IDU
(lyso
som
al en
zym
e) c
onjug
ate
incre
ased
IDU
brain
enz
yme
activ
ity
~
4-fo
ld
Opp
ortu
nity
• O
ffers
pro
mise
of a
n en
zym
e re
plac
emen
t th
erap
y
16"
0"0.2"
0.4"
0.6"
0.8"1"1.2"
IDU
MTf
- ID
U
Total"IDU"acEvity"
Capi
llarie
s Pa
renc
hym
a
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
am:"
MTf
+ id
uron
ate-
2-su
lfata
se (“
IDS”
)
Lyso
som
al St
orag
e Di
seas
es
Rare
inhe
rited
met
abol
ic di
seas
es c
ause
d by
an
enzy
me
defic
iency
prim
arily
affe
cting
chil
dren
Hunt
ers
Synd
rom
e (M
PS II)
Prob
lem
• M
PS II
is ca
used
by
an ID
S de
ficien
cy
• Cu
rrent
ly CN
S ef
fect
s un
treat
able
Resu
lts
• M
Tf +
IDS
(lyso
som
al en
zym
e) c
onjug
ate
incre
ased
IDS
brain
enz
yme
activ
ity
~2
0-fo
ld
Opp
ortu
nity
• O
ffers
pro
mise
of a
n en
zym
e re
plac
emen
t th
erap
y
17"
MTf
+ ID
S En
zym
e en
ters
the
brai
n tis
sue
Nat
ive
Enzy
me
does
not
ent
er th
e br
ain
tissu
e effi
caci
ously
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
am: "
MTf
+ D
oxor
ubici
n
• Do
xoru
bicin
is c
urre
ntly
used
as
a ca
ncer
tre
atm
ent (
e.g.
bre
ast,
blad
der,
lung,
ova
ries,
st
omac
h, th
yroi
d, m
ultip
le m
yelo
ma,
leuk
emias
and
Ho
dgkin
's ly
mph
oma)
Prob
lem
• Cu
rrent
ly do
es n
ot p
enet
rate
the
BBB
Resu
lts
• Si
gnific
ant I
NCRE
ASE
in br
ain u
ptak
e w
ith
the
MTf
+ D
oxor
ubici
n co
njuga
te V
S Do
xoru
bicin
alo
ne
Opp
ortu
nity
• W
ould
be
highly
effe
ctive
in tr
eatin
g br
ain
tum
ors
if it c
ould
be
deliv
ered
into
the
brain
18"
0.00"
1.00"
2.00"
3.00"
MTf
+ D
OXO
D
OXO
% IN
JEC
TED
DO
SE
(G T
ISSU
E/G
BO
DY
MAS
S)*1
00%
MTf
Sig
nific
antly
Enh
ance
s D
oxor
ubic
in T
rans
port
into
the
Brai
n
Conju
gate
reta
ins fu
ll ac
tivity
onc
e re
lease
d in
the
brain
OTCQ
X: B
IOAF
TS
X.V:
BTI
MTf
Sig
nifica
ntly
Redu
ces
Doxo
rubi
cin
Upta
ke in
to th
e He
art
Prob
lem
• Do
xoru
bicin
’s m
ost s
erio
us a
dver
se
effe
ct is
life-
thre
aten
ing h
eart
dam
age
Resu
lts
• M
Tf +
Dox
orub
icin
VS D
oxor
ubici
n on
its
own
show
ed a
sig
nifica
nt
DECR
EASE
in u
ptak
e in
the
hear
t
Solut
ion
• Co
uld b
e us
ed to
trea
t bra
in ca
ncer
s an
d de
crea
se h
eart-
upta
ke
side
effe
ct, o
fferin
g inc
reas
ed
usag
e
19"
0.0"
5.0"
10.0"
15.0"
20.0"
% INJECTED DOSE (gram brain tissue/gram body
mass)*100
MTf
+ D
OXO
D
OXO
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
am: "
MTf
+ T
rast
uzum
ab (H
erce
ptin®
)
• Tr
astu
zum
ab (H
erce
ptin®
)1 is
a hu
man
ized
mon
oclo
nal a
ntib
ody
used
to tr
eat H
ER2+
bre
ast c
ance
r •
Annu
al gl
obal
sales
~$6
.6 b
n2
• He
rcep
tin®
incr
ease
s su
rviva
l rat
e bu
t ~40
% p
atien
ts e
vent
ually
de
velo
p br
east
can
cer m
etas
tasis
in
the
brain
3
• Tr
astu
zum
ab (H
erce
ptin®
) doe
s no
t cr
oss
the
BBB
20"
1) H
erce
ptin
® is
a re
gist
ered
trad
emar
k of
Roc
he/G
enen
tech
2) C
ompa
ny R
epor
ted
Data
– 2
013
3) B
ritta
Wei
gelt,
Joh
anne
s L.
Pet
erse
& L
aura
J. v
an't
Veer
. (20
05, A
ugus
t). B
reas
t can
cer
met
asta
sis: m
arke
rs a
nd m
odel
s. N
atur
e Re
view
s Ca
ncer
5 ,
591-
602.
Brai
n C
apill
arie
s
Cel
l Nuc
lei
MTf
+ T
rast
uzum
ab (H
erce
ptin
®)
Conf
ocal
Imag
e Pe
rform
ed b
y iC
aptu
re a
t St
. Pau
l’s H
ospi
tal V
anco
uver
Can
ada
MTf
+ T
rast
uzum
ab (H
erce
ptin
®)
Con
foca
l Im
ages
Tw
o H
ours
Pos
t IV
Adm
inis
trat
ion
OTCQ
X: B
IOAF
TS
X.V:
BTI
Redu
ced
the
num
ber o
f HER
2+ b
reas
t ca
ncer
tum
ors
in th
e br
ain b
y 68
%
MTf
+ T
rast
uzum
ab (H
erce
ptin®
) "In
Vivo
Effic
acy
in Br
east
Can
cer M
odel
21"
0"10"
20"
30"
40"
50"
60"
70"
80"
90"
MTf
""
TZM
" M
Tf-T
ZM "
Salin
e "
""
""
""
Co
ntro
l !
Num
ber o
f Tum
ors
Addi
tiona
l Hig
hligh
ts:
• Th
e tu
mor
s th
at re
main
ed a
fter
treat
men
t had
57%
sm
aller
tu
mou
r vol
ume
• Pe
netra
ted
the
Bloo
d Tu
mou
r Ba
rrier
10
times
bet
ter t
han
Herc
eptin
® a
lone
•
Incr
ease
d ca
ncer
killi
ng e
ffect
of
Herc
eptin
® w
hen
linke
d w
ith
MTf
OTCQ
X: B
IOAF
TS
X.V:
BTI
Deve
lopm
ent P
rogr
am: "
MTf
p +
siRNA
Small
Inte
rferin
g RN
A (si
RNA)
• Si
lence
s ta
rget
gen
e ex
pres
sion
•
Targ
eted
gen
e as
socia
ted
with
hum
an d
iseas
es
(i.e
. can
cers
, neu
rode
gene
rativ
e di
seas
es, m
etab
olic
dise
ases
, etc
.)
Prob
lem
• siR
NA d
oes
not c
ross
the
BBB
• G
ene
targ
eting
with
in th
e br
ain is
cur
rent
ly un
achie
vabl
e
Resu
lts
• M
Tf+
siRNA
con
jugat
e de
liver
ed in
to th
e br
ain ti
ssue
•
Dem
onst
rate
d 40
% to
50%
dec
reas
e in
targ
et g
ene
VS s
iRNA
alo
ne
Opp
ortu
nity
• A
pote
ntial
cor
ners
tone
tech
nolo
gy fo
r the
dev
elopm
ent o
f new
th
erap
eutic
s su
ppre
ssing
dise
ase-
linke
d ge
nes
in th
e br
ain
22"
Natio
nal R
esea
rch
Coun
cil
NO
siR
NA
dete
cted
in B
rain
MTf
+ s
iRN
A de
tect
ed in
Bra
in
OTCQ
X: B
IOAF
TS
X.V:
BTI
Mar
ket P
rofile
"
23"
Data
sou
rce:
S&P
Cap
ital I
Q
Trai
ling
twel
ve m
onth
s as
of M
ay 2
014
Shar
es –
Sep
tem
ber 3
, 201
4
TSX.
V:BT
I; OTC
QX:
BIOA
F Sh
ares
Issu
ed &
Out
stan
ding
43
,805
,507
Fu
lly D
ilute
d
51,6
05,6
09
Opt
ions
5,
855,
625
Dire
ctor
s, o
fficer
s &
empl
oyee
s
War
rant
s
1,94
4,47
7
IP W
arra
nts
Mar
ket C
ap
~$
52.7
m
@ $
1.20
Sha
re P
rice
(Sep
t. 3,
201
4)
Cash
Pos
ition
~$
3m
(May
201
4 Fin
ancia
ls +
Augu
st 2
014
Finan
cing)
Ow
ners
hip
Insid
ers
& Af
filiat
es ~
35%
In
stitu
tiona
l ~10
%
OTCQ
X: B
IOAF
TS
X.V:
BTI 24"
Pipe
line
Brain
Tr
ansp
ort
Brain
Q
uant
ificat
ion
Cellu
lar
Loca
lizat
ion
PD M
odels
Ef
ficac
y
Oncology
Doxo
rubi
cin
[Glio
mas
] Pa
clita
xel
[Tum
ours
] He
rcep
tin
[Bre
ast C
ance
r] Ce
tuxim
ab
[Lun
g Ca
ncer
]
LSD
Hurle
rs S
yndr
ome
MPS
l M
odel
Hunt
ers
Synd
rom
e M
PS II
Mod
el
Sand
hoff
and
Tay-
Sac
s Di
seas
e He
xosa
mini
dase
B M
odel
siRNA
Stro
ke M
odel
ALS
Mod
el
OTCQ
X: B
IOAF
TS
X.V:
BTI
Sum
mar
y
25"
!In
telle
ctua
l Pr
oper
ty
& Co
llabo
ratio
ns
St
rong
pat
ent p
rote
ctio
n Pa
tent
por
tfolio
of >
30 p
aten
ts
Larg
e ph
arm
aceu
tical
colla
bora
tions
Po
sitive
resu
lts;
succ
essf
ul de
mon
stra
tion
Larg
e M
arke
t O
ppor
tunit
ies
Ab
ility
to e
xten
d pa
tent
life
Com
mer
cializ
e ne
w th
erap
eutic
s a
nd/o
r rev
italiz
e do
rman
t ca
ndid
ates
Co
ntrib
ute
to th
e gr
owth
in C
NS d
rug
mar
ket
"
Trea
tmen
t Po
tent
ial
M
etab
olic
dise
ases
Neur
odeg
ener
ative
di
seas
es
Onc
olog
y
"
Aw
arded
TS
X.V
Top
50
® in
2013
Lead
er in
pro
viding
sha
reho
lder v
alue
Mar
ket P
rofile
Goo
d ca
sh p
ositio
n Cl
ean
shar
e st
ruct
ure
Exit
stra
tegy
in p
lace
High
inte
rnal
owne
rship
Man
agem
ent
M
ajor s
ucce
ss in
: Dr
ug c
omm
ercia
lizat
ion
Biot
echn
olog
y &
vent
ure
capi
tal s
tartu
ps
Acad
emia
"
Tr
ansc
end
Prog
ram
“The fi
rst
natu
ral
carr
ier
to e
ffectiv
ely
tr
ansp
ort
thera
peutic
d
rugs
into
the b
rain
.”
Disc
over
y
of M
Tfp
Enha
nced
tech
nolo
gy
Gre
ater
com
mer
cial
pote
ntial
"
top related